- Home
- Products
- Customized ADCs
- TNFRSF8
- Anti-TNFRSF8-β-glucuronide-doxorubicin propyloxazoline ADC-12
Anti-TNFRSF8-β-glucuronide-doxorubicin propyloxazoline ADC-12 (CAT#: ADC-W-353)
This ADC product is comprised of an anti-TNFRSF8 monoclonal antibody (cCA10) conjugated via a β-glucuronide linker to a doxorubicin propyloxazoline (DPO). The doxorubicin propyloxazoline (DPO) is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, doxorubicin propyloxazoline (DPO) binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- TNFRSF8
- Alternative Names
- TNFRSF8; tumor necrosis factor receptor superfamily, member 8; CD30; Ki-1; D1S166E; tumor necrosis factor receptor superfamily member 8; Ki-1 antigen; CD30L receptor; cytokine receptor CD30; lymphocyte activation antigen CD30;
- Target Entrez Gene ID
- 943
- Target UniProt ID
- A5D8T4
- Overview
- The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is expressed by activated, but not by resting, T and B cells. TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB. This receptor is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported.
- Overview
- Chimeric Anti-TNFRSF8 Antibody, cAC10
- Generic name
- cAC10
- Species Reactivity
- Human
- Name
- β-glucuronide linker
- Description
- β-Glucuronide linkers belong to Enzymatically cleavable linkers, which have expected stability and provide facile release of the active drug. The cleavage of the β-glucuronide glycosidic bond relies on lysosomal enzyme β-glucuronidase, and this enzyme is abundantly present within lysosomes and is overexpressed in some tumor types, while the enzyme activity outside cells is low.
- Name
- doxorubicin propyloxazoline (DPO)
- Description
- Doxorubicin is a type of anti-cancer chemotherapy drug called an anthracycline. Doxorubicin works by blocking an enzyme called TopoisomeraseⅡthat cancer cells need to divide and grow.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-NOTCH2 (Tarextumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-2221)
- Anti-S. aureus ClfA (Tefibazumab)-MC-MMAF ADC (CAT#: ADC-W-2134)
- Anti-CTLA4 (Ipilimumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1001)
- Anti-MUC16-VC-MMAF ADC-2 (CAT#: ADC-W-239)
- Anti-CD72-MCC-DM1 ADC (CAT#: ADC-W-610)
- Anti-HGF (Rilotumumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1187)
- Anti-DLL4 (Demcizumab)-SMCC-DM1 ADC (CAT#: ADC-W-1016)
- Anti-C5 (Pexelizumab)-SMCC-DM1 ADC (CAT#: ADC-W-734)
- Anti-EGFR (Imgatuzumab)-SPDB-DM4 ADC (CAT#: ADC-W-1065)
- Anti-TNFSF11 (Denosumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-2239)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-353. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
| CAT# | Product Name | Linker | Payload |
| ADC-W-2343 | Anti-TNFRSF8 (Brentuximab )-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-465 | Anti-TNFRSF8 (Brentuximab)-VC-PAB-MMAE ADC | VC-PAB (valine-citrulline with PAB) | MMAE (Monomethyl auristatin E) |
| ADC-W-1887 | Anti-TNFRSF8 (Iratumumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| ADC-W-1889 | Anti-TNFRSF8 (Iratumumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-2344 | Anti-TNFRSF8 (Brentuximab )-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-350 | Anti-TNFRSF8-β-glucuronide-CBI Minor Groove Binder ADC-14 | β-glucuronide linker | CBI Minor Groove Binder |
| ADC-W-352 | Anti-TNFRSF8-β-glucuronide-MMAF ADC-12 | β-glucuronide linker | MMAF (Monomethyl auristatin F) |
| ADC-W-373 | Anti-CD70-β-glucuronide-CBI Minor Groove Binder ADC-5 | β-glucuronide linker | CBI Minor Groove Binder |
| ADC-W-376 | Anti-CD70-β-glucuronide-doxorubicin ADC-5 | β-glucuronide linker | doxorubicin |
| ADC-W-372 | Anti-CD70-β-glucuronide-Camptothecin Analog ADC-5 | β-glucuronide linker | Camptothecin Analog |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
